Tarsus Pharmaceuticals, Inc. TARS
Deals with insiders in the proxy filed Apr 28, 2026
Proxy, Item 404Deals between TARS and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 28, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 28, 2025.
Consulting Agreement with David E.I. Pyott“On April 24, 2022, prior to his appointment to our Board, we entered into a consulting agreement with David E.I. Pyott (as amended most recently on April 24, 2025, the “Pyott Consulting Agreement”) under which Mr. Pyott served as an advisor to the Company. The Pyott Consulting Agreement provided for Mr. Pyott to receive annual cash compensation of $25,000. Additionally, Mr. Pyott was granted an option to purchase 2,128 shares of our Common Stock pursuant to the Pyott Consulting Agreement, with an exercise price of $32.61 per share, as well as 1,383 RSUs. Pursuant to the existing terms of his outstanding options and RSUs, Mr. Pyott will continue to vest in his outstanding options and RSUs as he continues to provide services to us pursuant to the Pyott Consulting Agreement. The Pyott Consulting Agreement was terminated effective February 18, 2026, as he was appointed to the Company’s Board of Directors. The Pyott Consulting Agreement contained standard confidentiality, indemnification and intellectual property assignment provisions in favor of the Company.”
Read it in the proxyopen_in_new
Equity Investment in Privately-Held Eye Care Company“In April 2024, we participated in an equity round of an early clinical-stage private eye care company. Pursuant to the terms of a Preferred Stock Purchase Agreement we purchased $3.0 million of preferred stock. In December 2025, pursuant to the terms of an Amended Preferred Stock Purchase Agreement, the Company purchased an additional $0.9 million of preferred stock, resulting in a total investment of $3.9 million and representing a small minority equity interest in this private company. Dr. Azamian, the Company’s CEO and Chair of the Board, and Dr. Link, a member of the Company’s Board of Directors, serve on the board of this private company.”
Read it in the proxyopen_in_new
No longer reported 1 paragraph of the proxy filed Apr 28, 2025 with nothing like them this year
Investors' Rights Agreement“We are party to an amended and restated investors’ rights agreement with certain holders of our capital stock, including Flying L Investments XI, LLC, and Dr. Azamian. Under our investors’ rights agreement, certain holders of our capital stock have the right to demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing.”
Read it in last year's proxyopen_in_new
The whole section
As filed
6 paragraphs quoted as filed
Policies and Procedures for Related Party Transactions“We adopted a formal written policy providing that we are not permitted to enter into any transaction, arrangement, or relationship (or series of similar transactions, arrangements, or relationships) that exceeds $120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. As provided by our audit committee charter, our audit committee has the primary responsibility for the review, approval and oversight of such “related person transactions.” Under our related person transaction policy, our management is required to submit any related person transaction not previously approved or ratified by our audit committee to our audit committee. In approving or rejecting the proposed transactions, our audit committee takes into account all of the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction. Our audit committee will approve only those transactions that, as determined by our audit committee, are in, or are not inconsistent with, our best interests and the best interests of our stockholders.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“We entered into the Investors’ Rights Agreement prior to the adoption of this policy. Although we did not have a written policy for the review and approval of transactions with related persons prior to becoming a public reporting Company, our Board of Directors historically reviewed and approved any transaction in which a director or officer had a financial interest, including the Investors’ Rights Agreement described below. Prior to approving such a transaction, the material facts as to relationship or interest of the relevant director, officer or holder of 5% or more of any class of our voting securities in the agreement or transaction was disclosed to our Board of Directors. Our Board of Directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders.”
Read it in the proxyopen_in_new
Related Party Transactions“In addition to the compensation arrangements with directors and NEOs described elsewhere in this proxy statement, since January 1, 2025, we were involved in the following transactions in which we were or are a party involving an amount in excess of $120,000 and in which any director, executive officer, holder of more than 5% of our capital stock, or any member of the immediate family or person sharing the household with any of these individuals (other than tenants or employees), had or will have a direct or indirect material interest.”
Read it in the proxyopen_in_new
Consulting Agreement with David E.I. Pyott“On April 24, 2022, prior to his appointment to our Board, we entered into a consulting agreement with David E.I. Pyott (as amended most recently on April 24, 2025, the “Pyott Consulting Agreement”) under which Mr. Pyott served as an advisor to the Company. The Pyott Consulting Agreement provided for Mr. Pyott to receive annual cash compensation of $25,000. Additionally, Mr. Pyott was granted an option to purchase 2,128 shares of our Common Stock pursuant to the Pyott Consulting Agreement, with an exercise price of $32.61 per share, as well as 1,383 RSUs. Pursuant to the existing terms of his outstanding options and RSUs, Mr. Pyott will continue to vest in his outstanding options and RSUs as he continues to provide services to us pursuant to the Pyott Consulting Agreement. The Pyott Consulting Agreement was terminated effective February 18, 2026, as he was appointed to the Company’s Board of Directors. The Pyott Consulting Agreement contained standard confidentiality, indemnification and intellectual property assignment provisions in favor of the Company.”
Read it in the proxyopen_in_new
Equity Investment in Privately-Held Eye Care Company“In April 2024, we participated in an equity round of an early clinical-stage private eye care company. Pursuant to the terms of a Preferred Stock Purchase Agreement we purchased $3.0 million of preferred stock. In December 2025, pursuant to the terms of an Amended Preferred Stock Purchase Agreement, the Company purchased an additional $0.9 million of preferred stock, resulting in a total investment of $3.9 million and representing a small minority equity interest in this private company. Dr. Azamian, the Company’s CEO and Chair of the Board, and Dr. Link, a member of the Company’s Board of Directors, serve on the board of this private company.”
Read it in the proxyopen_in_new
Indemnification Agreements“We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements and our certificate of incorporation and bylaws require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.